Filters
Term Search
You can select from the dropdown list OR enter your own terms to refine the search.
Last Updated: 10/31/2025
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 70 publications
Future treatments for myelin oligodendrocyte glycoprotein antibody-associated disease: the clinical trial landscape.
Journal: Expert opinion on emerging drugs
Published: September 23, 2025
Blocking the neonatal Fc receptor as a novel approach to prevent cardiac neonatal lupus: a proof-of-concept study.
Journal: Annals of the rheumatic diseases
Published: August 26, 2025
Self-administration of rozanolixizumab via manual push and infusion pump methods in patients with generalised myasthenia gravis: a randomised, phase 3, open-label, crossover study.
Journal: Journal of neurology
Published: July 23, 2025
Aseptic Meningitis Following Rozanolixizumab in a Patient With Refractory Anti-MuSK Positive Myasthenia Gravis: A Case Report.
Journal: The Neurohospitalist
Published: July 20, 2025
From promise to practice: evaluating the clinical impact of FcRn inhibition in IgG-mediated autoimmune rheumatic diseases.
Journal: Frontiers in immunology
Published: June 30, 2025
A comprehensive review of the treatment options in myasthenia gravis.
Journal: Disease-a-month : DM
Published: June 21, 2025
Rozanolixizumab for Myasthenia Gravis: a breakthrough treatment and future prospects.
Journal: Immunotherapy
Published: April 25, 2025
Efficacy and safety of FcRn inhibitors in patients with Myasthenia gravis: An updated systematic review and meta‑analysis.
Journal: Clinical neurology and neurosurgery
Published: March 18, 2025
Long-term safety of cyclical rozanolixizumab in patients with generalized myasthenia gravis: Results from the Phase 3 MycarinG study and an open-label extension.
Journal: Journal of neuromuscular diseases
Published: March 04, 2025
Rozanolixizumab in generalized myasthenia gravis: Pooled analysis of the Phase 3 MycarinG study and two open-label extensions.
Journal: Journal of neuromuscular diseases
Published: March 04, 2025
Real-World Experience with FcRn Inhibitors Efgartigimod and Rozanolixizumab in Myasthenia Gravis: Administration in Multiple Cycles and Transition from Intravenous to Subcutaneous Formulation.
Journal: Neurology and therapy
Published: March 04, 2025
Last Updated: 10/31/2025